Johnson & Johnson (JNJ) on Thursday said it is expanding the U.S. rollout of its TECNIS PureSee intraocular lens, an extended depth of focus lens designed to improve vision for patients undergoing cataract surgery.
The company said TECNIS PureSee is the first and only U.S. Food and Drug Administration-approved extended depth of focus intraocular lens without a warning on loss of contrast sensitivity, a measure of a patient's ability to distinguish objects from their background, particularly in low-light conditions.
Johnson & Johnson said the lens provides strong distance and intermediate vision with some near vision, while 97% of patients reported no very bothersome visual disturbances.
"With the full U.S. availability of TECNIS PureSee IOL, we are expanding access to an important extended depth of focus option that reflects our commitment to innovation, visual quality, and patient satisfaction," said Erin Powers, President, Surgical Vision, North America, Johnson & Johnson.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.